Arrivent Biopharma Inc (AVBP)

$28.19 -0.93 (-3.19%)
Market Cap 1.44B
Revenue (ttm) 0.00
Net Income (ttm) -166.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 80,646
Avg Vol 540,524
Day's Range N/A - N/A
Shares Out 49.31M
Stochastic %K 18%
Beta 1.36
Analysts Strong Sell
Price Target $44.82

Company Profile

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment o...

Industry: Biotechnology
Sector: Healthcare
Phone: 628 277 4836
Address:
18 Campus Boulevard, Suite 100, Newtown Square, United States
StochAlpha
StochAlpha Aug. 20 at 12:05 PM
Sector Heat Map · Aug 20 · 12 Signals. Real Estate Leads. Thin cut today. Real Estate leads with 4 signals $FTRE showing up there. Healthcare and Tech each very light. $AVBP on the healthcare side, $AAPL the lone tech name. Consumer Discretionary, Energy, Industrials, dark. Market is not giving a lot to work with today. What's there is defensive. See Top 5 Buys / Sells posted a few minutes ago.
0 · Reply
laaarsas
laaarsas Aug. 19 at 6:44 PM
$AVBP WHERE IS THE SAP FOR FURVENT?!
0 · Reply
27R
27R Aug. 18 at 3:34 PM
$AVBP Buckle up — earnings after the close today.
0 · Reply
Quantumup
Quantumup Aug. 17 at 11:36 AM
H.C. Wainwright⬆️ $AVBP's PT to $47 and reiterated Buy. $CGON $ORIC JNJ AZN SMMT BDTX Here's what H.C. Wainwright said in its note to investors: https://x.com/Quantumup1/status/2089314943409574282?s=20
0 · Reply
laaarsas
laaarsas Aug. 13 at 2:43 PM
$AVBP Can anyone get their hands on the SAP for FURVENT?
1 · Reply
Monkey7779192
Monkey7779192 Aug. 12 at 11:16 PM
$AVBP They delayed it. Something isnt right.
2 · Reply
justiceforb_85
justiceforb_85 Aug. 12 at 8:34 PM
$AVBP not quite sure what to make of delay in data release. Still remain optimistic.
0 · Reply
judgeyoung2
judgeyoung2 Aug. 12 at 8:26 PM
$AVBP from the beginning of the year to the middle to the second half lol
1 · Reply
laaarsas
laaarsas Aug. 11 at 3:42 PM
$AVBP Why?!?
0 · Reply
justiceforb_85
justiceforb_85 Aug. 10 at 9:57 PM
$AVBP patiently waiting for firmonertinib data.
0 · Reply
Latest News on AVBP
ArriVent Biopharma price target raised to $47 from $44 at H.C. Wainwright

2026-08-17T10:20:18.000Z - 7 days ago

ArriVent Biopharma price target raised to $47 from $44 at H.C. Wainwright

ArriVent Biopharma price target lowered to $40 from $43 at Citi

2026-08-17T08:17:10.000Z - 7 days ago

ArriVent Biopharma price target lowered to $40 from $43 at Citi

ArriVent BioPharma Reports Second Quarter 2026 Financial Results

Aug 12, 2026, 4:01 PM EDT - 11 days ago

ArriVent BioPharma Reports Second Quarter 2026 Financial Results

ArriVent BioPharma Earnings release: Q2 2026

Aug 12, 2026, 4:00 PM EDT - 11 days ago

ArriVent BioPharma Earnings release: Q2 2026

ArriVent BioPharma Quarterly report: Q2 2026

Aug 12, 2026, 4:00 PM EDT - 11 days ago

ArriVent BioPharma Quarterly report: Q2 2026

ArriVent BioPharma Slides: Corporate presentation

Aug 12, 2026, 7:00 AM EDT - 12 days ago

ArriVent BioPharma Slides: Corporate presentation

ArriVent BioPharma Transcript: AGM 2026

Jun 18, 2026, 12:00 PM EDT - 2 months ago

ArriVent BioPharma Transcript: AGM 2026

ArriVent Biopharma assumed with a Buy at Truist

2026-05-29T14:49:43.000Z - 3 months ago

ArriVent Biopharma assumed with a Buy at Truist

ArriVent Biopharma price target lowered to $43 from $45 at Citi

2026-05-13T10:44:40.000Z - 3 months ago

ArriVent Biopharma price target lowered to $43 from $45 at Citi

ArriVent Biopharma reports Q1 EPS (96c), consensus (89c)

2026-05-11T21:38:55.000Z - 3 months ago

ArriVent Biopharma reports Q1 EPS (96c), consensus (89c)

ArriVent BioPharma Reports First Quarter 2026 Financial Results

May 11, 2026, 4:01 PM EDT - 3 months ago

ArriVent BioPharma Reports First Quarter 2026 Financial Results

ArriVent BioPharma Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 3 months ago

ArriVent BioPharma Earnings release: Q1 2026

ArriVent BioPharma Quarterly report: Q1 2026

May 11, 2026, 4:00 PM EDT - 3 months ago

ArriVent BioPharma Quarterly report: Q1 2026

ArriVent BioPharma Slides: Corporate presentation

May 11, 2026, 4:00 PM EDT - 3 months ago

ArriVent BioPharma Slides: Corporate presentation

ArriVent Biopharma announces FDA clearance of ARR-002 NDA

2026-05-07T18:45:02.000Z - 3 months ago

ArriVent Biopharma announces FDA clearance of ARR-002 NDA

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

May 7, 2026, 8:00 AM EDT - 3 months ago

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

ArriVent BioPharma Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

ArriVent BioPharma Proxy statement: Proxy filing

ArriVent BioPharma Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

ArriVent BioPharma Proxy statement: Proxy filing

Citi ups ArriVent target, opens ‘upside 90-day catalyst watch’

2026-04-24T11:06:33.000Z - 4 months ago

Citi ups ArriVent target, opens ‘upside 90-day catalyst watch’

ArriVent Biopharma price target raised to $45 from $37 at B. Riley

2026-03-23T12:51:34.000Z - 5 months ago

ArriVent Biopharma price target raised to $45 from $37 at B. Riley

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

Mar 17, 2026, 5:00 PM EDT - 5 months ago

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

ArriVent Biopharma assumed with a Buy at BTIG

2026-03-11T20:28:14.000Z - 5 months ago

ArriVent Biopharma assumed with a Buy at BTIG

ArriVent Biopharma price target raised to $50 from $44 at Oppenheimer

2026-03-06T12:53:00.000Z - 6 months ago

ArriVent Biopharma price target raised to $50 from $44 at Oppenheimer

ArriVent Biopharma price target raised to $44 from $42 at H.C. Wainwright

2026-03-06T11:15:50.000Z - 6 months ago

ArriVent Biopharma price target raised to $44 from $42 at H.C. Wainwright

ArriVent Biopharma price target raised to $33 from $31 at Citi

2026-03-06T11:00:30.000Z - 6 months ago

ArriVent Biopharma price target raised to $33 from $31 at Citi

ArriVent BioPharma Reports Full Year 2025 Financial Results

Mar 5, 2026, 4:01 PM EST - 6 months ago

ArriVent BioPharma Reports Full Year 2025 Financial Results

ArriVent BioPharma Annual report: Q4 2025

Mar 5, 2026, 9:30 AM EST - 6 months ago

ArriVent BioPharma Annual report: Q4 2025

ArriVent BioPharma Earnings release: Q4 2025

Mar 5, 2026, 9:30 AM EST - 6 months ago

ArriVent BioPharma Earnings release: Q4 2025

Omega takes new stake in Rocket Companies, exits ArriVent Biopharma

2026-02-17T15:25:37.000Z - 6 months ago

Omega takes new stake in Rocket Companies, exits ArriVent Biopharma

ABR AESI APO DMAC ET GEHC MANU

ArriVent Biopharma initiated with an Overweight at Cantor Fitzgerald

2025-12-22T21:20:44.000Z - 8 months ago

ArriVent Biopharma initiated with an Overweight at Cantor Fitzgerald

ArriVent Biopharma announces first patient dosed in Phase 3 ALPACCA study

2025-12-22T13:06:00.000Z - 8 months ago

ArriVent Biopharma announces first patient dosed in Phase 3 ALPACCA study

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

Dec 22, 2025, 8:00 AM EST - 8 months ago

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

ArriVent Biopharma initiated with a Buy at BTIG on firmonertinib potential

2025-12-10T11:46:01.000Z - 9 months ago

ArriVent Biopharma initiated with a Buy at BTIG on firmonertinib potential

ArriVent Biopharma initiated with a Buy at BTIG

2025-12-10T11:40:54.000Z - 9 months ago

ArriVent Biopharma initiated with a Buy at BTIG

ArriVent Biopharma initiated with a Buy at Truist

2025-11-25T11:25:25.000Z - 9 months ago

ArriVent Biopharma initiated with a Buy at Truist

ArriVent BioPharma Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 8:00 AM EST - 10 months ago

ArriVent BioPharma Reports Third Quarter 2025 Financial Results

ArriVent BioPharma Earnings release: Q3 2025

Nov 10, 2025, 8:00 AM EST - 10 months ago

ArriVent BioPharma Earnings release: Q3 2025

ArriVent BioPharma Quarterly report: Q3 2025

Nov 10, 2025, 8:00 AM EST - 10 months ago

ArriVent BioPharma Quarterly report: Q3 2025

ArriVent Appoints Brent S. Rice as Chief Commercial Officer

Sep 22, 2025, 4:05 PM EDT - 11 months ago

ArriVent Appoints Brent S. Rice as Chief Commercial Officer

Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

Sep 9, 2025, 8:00 AM EDT - 1 year ago

Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

ArriVent BioPharma Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Reports Second Quarter 2025 Financial Results

ArriVent BioPharma Quarterly report: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Quarterly report: Q2 2025

ArriVent BioPharma Earnings release: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Earnings release: Q2 2025

ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026

Jul 21, 2025, 8:00 AM EDT - 1 year ago

ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026

ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Jul 1, 2025, 11:15 PM EDT - 1 year ago

ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Jul 1, 2025, 4:05 PM EDT - 1 year ago

ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants

ArriVent BioPharma Press release: Study Update

Jun 23, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Press release: Study Update

ArriVent BioPharma Slides: Study Update

Jun 23, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Slides: Study Update

ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study

Jun 23, 2025, 7:00 AM EDT - 1 year ago

ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

Jun 20, 2025, 4:05 PM EDT - 1 year ago

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

ArriVent BioPharma Reports First Quarter 2025 Financial Results

May 12, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Reports First Quarter 2025 Financial Results

ArriVent BioPharma Quarterly report: Q1 2025

May 12, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Quarterly report: Q1 2025

ArriVent BioPharma Earnings release: Q1 2025

May 12, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Earnings release: Q1 2025

ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

Apr 28, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

ArriVent BioPharma Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Proxy statement: Proxy Filing

ArriVent BioPharma Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Proxy statement: Proxy Filing

ArriVent BioPharma Reports Full Year 2024 Financial Results

Mar 3, 2025, 7:00 AM EST - 1 year ago

ArriVent BioPharma Reports Full Year 2024 Financial Results

ArriVent BioPharma Earnings release: Q4 2024

Mar 3, 2025, 7:00 AM EST - 1 year ago

ArriVent BioPharma Earnings release: Q4 2024

ArriVent BioPharma Annual report: Q4 2024

Mar 3, 2025, 7:00 AM EST - 1 year ago

ArriVent BioPharma Annual report: Q4 2024

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

Jan 21, 2025, 7:00 PM EST - 1 year ago

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

ArriVent BioPharma Quarterly report: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

ArriVent BioPharma Quarterly report: Q3 2024

ArriVent BioPharma Earnings release: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

ArriVent BioPharma Earnings release: Q3 2024

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

Sep 9, 2024, 12:05 PM EDT - 2 years ago

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma

Aug 15, 2024, 7:01 AM EDT - 2 years ago

Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma

ArriVent BioPharma Reports Second Quarter 2024 Financial Results

Aug 14, 2024, 4:01 PM EDT - 2 years ago

ArriVent BioPharma Reports Second Quarter 2024 Financial Results

ArriVent BioPharma Quarterly report: Q2 2024

Aug 14, 2024, 4:00 PM EDT - 2 years ago

ArriVent BioPharma Quarterly report: Q2 2024

ArriVent BioPharma Earnings release: Q2 2024

Aug 14, 2024, 4:00 PM EDT - 2 years ago

ArriVent BioPharma Earnings release: Q2 2024

ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

Aug 12, 2024, 8:00 AM EDT - 2 years ago

ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

Jun 5, 2024, 7:00 AM EDT - 2 years ago

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

ArriVent Appoints John Hohneker, M.D., to its Board of Directors

May 16, 2024, 4:05 PM EDT - 2 years ago

ArriVent Appoints John Hohneker, M.D., to its Board of Directors

ArriVent BioPharma Reports First Quarter 2024 Financial Results

May 8, 2024, 8:00 AM EDT - 2 years ago

ArriVent BioPharma Reports First Quarter 2024 Financial Results

ArriVent BioPharma Quarterly report: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

ArriVent BioPharma Quarterly report: Q1 2024

ArriVent BioPharma Earnings release: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

ArriVent BioPharma Earnings release: Q1 2024

ArriVent Appoints Kristine Peterson to its Board of Directors

Apr 22, 2024, 4:05 PM EDT - 2 years ago

ArriVent Appoints Kristine Peterson to its Board of Directors

InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

Mar 28, 2024, 8:30 PM EDT - 2 years ago

InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

ArriVent BioPharma Reports Full Year 2023 Financial Results

Mar 28, 2024, 4:05 PM EDT - 2 years ago

ArriVent BioPharma Reports Full Year 2023 Financial Results

StochAlpha
StochAlpha Aug. 20 at 12:05 PM
Sector Heat Map · Aug 20 · 12 Signals. Real Estate Leads. Thin cut today. Real Estate leads with 4 signals $FTRE showing up there. Healthcare and Tech each very light. $AVBP on the healthcare side, $AAPL the lone tech name. Consumer Discretionary, Energy, Industrials, dark. Market is not giving a lot to work with today. What's there is defensive. See Top 5 Buys / Sells posted a few minutes ago.
0 · Reply
laaarsas
laaarsas Aug. 19 at 6:44 PM
$AVBP WHERE IS THE SAP FOR FURVENT?!
0 · Reply
27R
27R Aug. 18 at 3:34 PM
$AVBP Buckle up — earnings after the close today.
0 · Reply
Quantumup
Quantumup Aug. 17 at 11:36 AM
H.C. Wainwright⬆️ $AVBP's PT to $47 and reiterated Buy. $CGON $ORIC JNJ AZN SMMT BDTX Here's what H.C. Wainwright said in its note to investors: https://x.com/Quantumup1/status/2089314943409574282?s=20
0 · Reply
laaarsas
laaarsas Aug. 13 at 2:43 PM
$AVBP Can anyone get their hands on the SAP for FURVENT?
1 · Reply
Monkey7779192
Monkey7779192 Aug. 12 at 11:16 PM
$AVBP They delayed it. Something isnt right.
2 · Reply
justiceforb_85
justiceforb_85 Aug. 12 at 8:34 PM
$AVBP not quite sure what to make of delay in data release. Still remain optimistic.
0 · Reply
judgeyoung2
judgeyoung2 Aug. 12 at 8:26 PM
$AVBP from the beginning of the year to the middle to the second half lol
1 · Reply
laaarsas
laaarsas Aug. 11 at 3:42 PM
$AVBP Why?!?
0 · Reply
justiceforb_85
justiceforb_85 Aug. 10 at 9:57 PM
$AVBP patiently waiting for firmonertinib data.
0 · Reply
laaarsas
laaarsas Aug. 9 at 7:45 PM
$AVBP When???
1 · Reply
justiceforb_85
justiceforb_85 Aug. 6 at 9:55 PM
$AVBP hopefully an update at next quarterly report?
0 · Reply
laaarsas
laaarsas Aug. 5 at 1:18 PM
$AVBP HOW?!
0 · Reply
laaarsas
laaarsas Aug. 5 at 7:33 AM
$AVBP Anyone with prediction on when data??
0 · Reply
laaarsas
laaarsas Aug. 4 at 5:10 PM
$AVBP YES YOU CAN!!!
0 · Reply
laaarsas
laaarsas Aug. 4 at 10:18 AM
$AVBP When!?!
0 · Reply
justiceforb_85
justiceforb_85 Aug. 4 at 1:48 AM
$AVBP still waiting on data. Good luck to all longs.
0 · Reply
laaarsas
laaarsas Aug. 3 at 7:38 PM
$AVBP when will it happen?
0 · Reply
laaarsas
laaarsas Aug. 3 at 2:25 PM
$AVBP They have stolen the data
0 · Reply
laaarsas
laaarsas Jul. 29 at 10:43 AM
$AVBP I can’t wait much longer. I can’t stand the wait.
1 · Reply
laaarsas
laaarsas Jul. 29 at 9:14 AM
$AVBP Where is insider buy?
0 · Reply
laaarsas
laaarsas Jul. 27 at 11:53 AM
$AVBP when is it?
1 · Reply